|
[1] ANDRONESCU CI,PURCAREA MR,BABES PA. Nonalcoholic fatty liver disease:Epidemiology, pathogenesis and therapeutic implications[J]. J Med Life, 2018, 11(1):20-23.
|
|
[2] CHALASANI N, YOUNOSSI Z, LAVINE JE, et al. The diagnosis and management of non-alcoholic fatty liver disease:Practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases,and American College of Gastroenterology[J]. Gastroenterology, 2012, 55(6):2005-2023.
|
|
[3] YOUNOSSI ZM, KOENIG AB, ABDELATIF D, et al. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64(1):73-84.
|
|
[4] PERUMPAIL BJ, ALI KM, YOO ER, et al. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease[J].World J Gastroenterol, 2017, 23(47):8263-8276.
|
|
[5] CHING-YEUNG YB, KWOK D, WONG VW. Magnitude of nonalcoholic fatty liver disease:Eastern perspective[J]. J Clin Exp Hepatol, 2019, 9(4):491-496.
|
|
[6] HUANG JF, TSAI PC, YEH ML, et al. Risk stratification of nonalcoholic fatty liver disease across body mass index in a community basis[J]. J Formos Med Assoc, 2020, 119(1 Pt 1):89-96.
|
|
[7] ESTES C, ANSTEE QUENTIN M, ARIAS-LOSTE MT, et al.Modeling NAFLD disease burden in China, France, Germany,Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030[J]. J Hepatol, 2018, 69(4):896-904.
|
|
[8] KUMAR R, MOHAN S. Non-alcoholic fatty liver disease in lean subjects:Characteristics and implications[J]. J Clin Transl Hepatol, 2017, 5(3):216-223.
|
|
[9] BORRELLI A, BONELLI P, TUCCILLO FM, et al. Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma:Current and innovative therapeutic approaches[J]. Redox Biology, 2018,15:467-479.
|
|
[10] SHI YW, WANG QY, SUN YM, et al. The prevalence of lean/nonobese nonalcoholic fatty liver disease:A systematic review and meta-analysis[J]. J Clin Gastroenterol, 2019.[Online ahead of print]
|
|
[11] LIU CJ. Prevalence and risk factors for non-alcoholic fatty liver disease in Asian people who are not obese[J]. J Gastroenterol Hepatol, 2012, 27(10):1555-1560.
|
|
[12] DAS K, DAS K, MUKHERJEE PS, et al. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant disease[J]. Hepatology, 2010, 51(5):1593-602.
|
|
[13] FENG RN, DU SS, WANG C, et al. Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population[J]. World J Gastroenterol,2014, 20(47):17932-17940.
|
|
[14] LEE SW, LEE TY, YANG SS, et al. Risk factors and metabolic abnormality of patients with non-alcoholic fatty liver disease:Either non-obese or obese Chinese population[J]. Hepatobiliary Pancreat Dis Int, 2018, 17(1):45-48.
|
|
[15] NADERIAN M, KOLAHDOOZAN S, SHARIFI AS, et al. Assessment of lean patients with nonalcoholic fatty liver disease in a middle income country; prevalence and its association with metabolic disorders:A cross-sectional study[J]. Arch Iran Med, 2017, 20(4):211-217.
|
|
[16] HAGSTRÖM H, NASR P, EKSTEDT M, et al. Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease:A long-term follow-up study[J]. Hepatol Commun, 2017, 2(1):48-57.
|
|
[17] GONZALEZ-CANTERO J, MARTIN-RODRIGUEZ JL, GONZALEZ-CANTERO A, et al. Insulin resistance in lean and overweight non-diabetic Caucasian adults:Study of its relationship with liver triglyceride content, waist circumference and BMI[J]. PLoS One, 2018, 13(2):e0192663.
|
|
[18] SUCCURRO E, MARINI MA, FRONTONI S, et al. Insulin secretion in metabolically obese, but normal weight, and in metabolically healthy but obese individuals[J]. Obesity(Silver Spring), 2008, 16(8):1881-1886.
|
|
[19] TU LN, SHOWALTER MR, CAJKA T, et al. Metabolomic characteristics of cholesterol-induced non-obese nonalcoholic fatty liver disease in mice[J]. Sci Rep, 2017, 7(1):6120.
|
|
[20] TOBARI M, HASHIMOTO E, TANIAI M, et al. Characteristics of non-alcoholic steatohepatitis among lean patients in Japan:Not uncommon and not always benign[J]. J Gastroenterol Hepatol, 2019, 34(8):1404-1410.
|
|
[21] SOOKOIAN S, PIROLA CJ. Systematic review with meta-analysis:Risk factors for non-alcoholic fatty liver disease suggest a shared altered metabolic and cardiovascular profile between lean and obese patients[J]. Aliment Pharmacol Ther,2017, 46(2):85-95.
|
|
[22] LI H, CHEN Y, TIAN X, et al. Comparison of clinical characteristics between lean and obese nonalcoholic fatty liver disease in the northeast Chinese population[J]. Arch Med Sci Atheroscler Dis, 2019, 4:e191-e195.
|
|
[23] KUMAR R, RASTOGI A, SHARMA MK, et al. Clinicopathological characteristics and metabolic profiles of non-alcoholic fatty liver disease in Indian patients with normal body mass index:Do they differ from obese or overweight non-alcoholic fatty liver disease?[J]. Indian J Endocrinol Metab, 2013, 17(4):665-671.
|
|
[24] MARGARITI E, DEUTSCH M, MANOLAKOPOULOS S, et al.Non-alcoholic fatty liver disease may develop in individuals with normal body mass index[J]. Ann Gastroenterol, 2012,25(1):45-51.
|
|
[25] NERVOSA ROSEN E, BAKSHI N, WATTERS A, et al. Hepatic complications of anorexia nervosa[J]. Dig Dis Sci, 2017, 62(11):2977-2981.
|
|
[26] ZHOU Y, WEI F, FAN Y. High serum uric acid and risk of nonalcoholic fatty liver disease:A systematic review and meta-analysis[J]. Clin Biochem, 2016, 49(7-8):636-642.
|
|
[27] ZHENG X, GONG L, LUO R, et al. Serum uric acid and non-alcoholic fatty liver disease in non-obesity Chinese adults[J]. Lipids Health Dis, 2017, 16(1):202.
|
|
[28] DARMAWAN G, HAMIJOYO L, HASAN I. Association between serum uric acid and non-alcoholic fatty liver disease:A Metaanalysis[J]. Acta Med Indones, 2017, 49(2):136-147.
|
|
[29] ANDERSON GJ, VULPE CD. Mammalian iron transport[J].Cell Mol Life Sci, 2009, 66(20):3241-3261.
|
|
[30] AKYUZ U, YESIL A, YILMAZ Y. Characterization of lean patients with nonalcoholic fatty liver disease:Potential role of high hemoglobin levels[J]. Scand J Gastroenterol, 2015, 50(3):341-346.
|
|
[31] PEVERILL W, POWELL LW, SKOIEN R. Evolving concepts in the pathogenesis of NASH:Beyond steatosis and inflammation[J]. Int J Mol Sci, 2014, 15(5):8591-8638.
|
|
[32] BUZZETTI E, PINZANI M, TSOCHATZIS EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease(NAFLD)[J]. Metabolism, 2016, 65(8):1038-1048.
|
|
[33] VIRKAMAKI A, KORSHENINNIKOVA E, SEPPALA-LINDROOS A, et al. Intramyocellular lipid is associated with resistance to in vivo insulin actions on glucose uptake, antilipolysis, and early insulin signaling pathways in human skeletal muscle[J].Diabetes, 2001, 50(10):2337-2343.
|
|
[34] GONZALEZ-CANTERO J, MARTIN-RODRIGUEZ JL, GONZALEZ-CANTERO A, et al. Insulin resistance in lean and overweight non-diabetic Caucasian adults:Study of its relationship with liver triglyceride content, waist circumference and BMI[J]. PLoS One, 2018, 13(2):e0192663.
|
|
[35] WEI JL, LEUNG JC, LOONG TC, et al. Prevalence and severity of nonalcoholic fatty liver disease in non-obese patients:A population study using proton-magnetic resonance spectroscopy[J]. Am J Gastroenterol, 2015, 110(9):1306-1315.
|
|
[36] BUGIANESI E, GASTALDELLI A, VANNI E, et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease:Sites and mechanisms[J]. Diabetologia, 2005,48(4):634-642.
|
|
[37] LEE YH, JUNG KS, KIM SU, et al. Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance:Nationwide surveys(KNHANES 2008-2011)[J]. J Hepatol,2015, 63(2):486-493.
|
|
[38] LEE MJ, KIM EH, BAE SJ, et al. Age-related decrease in skeletal muscle mass is an independent risk factor for incident nonalcoholic fatty liver disease:A 10-year retrospective cohort study[J]. Gut Liver, 2019, 13(1):67-76.
|
|
[39] BULL MJ, PLUMMER NT. Part 1:The human gut microbiome in health and disease[J]. Integr Med(Encinitas), 2014, 13(6):17-22.
|
|
[40] DUARTE SMB, STEFANO JT, MIELE L. Gut microbiome composition in lean patients with NASH is associated with liver damage independent of caloric intake:A prospective pilot study[J]. Nutr Metab Cardiovasc Dis, 2018, 28(4):369-387.
|
|
[41] ZHOU YJ, LI YY, NIE YQ, et al. Prevalence of fatty liver disease and its risk factors in the population of South China[J].World J Gastroenterol, 2007, 13(47):6419-6424.
|
|
[42] MOFIDI F, POUSTCHI H, YARI Z, et al. Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease:A pilot, randomised, double-blind, placebo-controlled, clinical trial[J]. Br J Nutr, 2017, 117(5):662-668.
|
|
[43] KWAK JH, JUN DW, LEE SM, et al. Lifestyle predictors of obese and non-obese patients with nonalcoholic fatty liver disease:A cross-sectional study[J]. Clin Nutr, 2018, 37(5):1550-1557.
|
|
[44] TU LN, SHOWALTER MR, CAJKA T, et al. Metabolomic characteristics of cholesterol-induced non-obese nonalcoholic fatty liver disease in mice[J]. Sci Rep, 2017, 7(1):6120.
|
|
[45] PETERSEN KF, DUFOUR S, HARIRI A, et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease[J]. N Engl J Med, 2010, 362(12):1082-1089.
|
|
[46] YUAN X, WATERWORTH D, PERRY JR, et al. Populationbased genome-wide association studies reveal six loci influencing plasma levels of liver enzymes[J]. Am J Hum Genet,2008, 83(4):520-528.
|
|
[47] ROMEO S, KOZLITINA J, XING C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease[J]. Nat Genet, 2008, 40(12):1461-1465.
|
|
[48] SHEN J, WONG GL, CHAN HL, et al. PNPLA3 gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome[J]. Aliment Pharmacol Ther, 2014, 38(5):532-539.
|
|
[49] SOOKOIAN S, PIROLA CJ. Systematic review with meta-analysis:The significance of histological disease severity in lean patients with nonalcoholic fatty liver disease[J]. Aliment Pharmacol Ther, 2018, 47(1):16-25.
|
|
[50] MATTEONI CA, YOUNOSSI ZM, GRAMLICH T, et al. Nonalcoholic fatty liver disease:A spectrum of clinical and pathological severity[J]. Gastroenterology, 1999, 116(6):1413-1419.
|
|
[51] YOUNES R, BUGIANESI E. NASH in lean individuals[J]. Semin Liver Dis, 2019, 39(1):86-95.
|
|
[52] ALAM S, JAHID HASAN M, KHAN MAS, et al. Effect of weight reduction on histological activity and fibrosis of lean nonalcoholic steatohepatitis patient[J]. J Transl Int Med, 2019, 7(3):106-114.
|
|
[53] IPSEN DH, ROLIN B, RAKIPOVSKI G, et al. Liraglutide decreases hepatic inflammation and injury in advanced lean non-alcoholic steatohepatitis[J]. Basic Clin Pharmacol Toxicol, 2018, 123(6):704-713.
|
DownLoad: